Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley Trims 3SBIO (01530.HK) TP to $34, Rating Overweight
Recommend 10 Positive 13 Negative 3 |
||||
|
||||
|
Morgan Stanley released a research report incorporating 3SBIO (01530.HK)'s 2025 results, and lowering its 2026-2028 revenue forecasts by 5%/ 7% / 6% each, due to reduced sales forecasts for 3SBIO's core commercialized product, TPIAO, and milestone payments, mainly affected by the depreciation of USD/ RMB. The broker also dropped the product gross profit margin and adjusted the operating expense ratio based on the latest trends, and cut its EPS forecasts for the same period by 8.3%/ 14.5%/ 12.4%, respectively. Therefore, Morgan Stanley trimmed its target price to $34 from $38, with rating at Overweight. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
